▶ PEG-MGF · SUBTOPIC · MECHANISM
PEG-MGF Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
PEGylated form of mechano growth factor (MGF), the IGF-1Ec splice variant produced locally in muscle in response to mechanical loading or injury. Drives satellite cell activation, proliferation, and local hypertrophy. PEG conjugation extends the otherwise sub-hour half-life to support practical research dosing.
PHARMACOKINETIC HALF-LIFE
Reported half-life for PEG-MGF: Several days (PEGylated vs. <30 minutes for native MGF). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
PEG-MGF is a defined sequence: C-terminal Ec exon: YQPPSTNKNTKSQRRKGSTFEERK (24 residues, PEGylated). Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
PEG-MGF is tagged in 1 mechanism category on PEPPUDEX. Each category aggregates the broader pharmacology of related compounds.
The growth hormone axis is regulated by two complementary upstream signals: GHRH (stimulatory, from the hypothalamus, acting on the GHRH receptor on pituitary somatotrophs) and ghrelin (stimulatory, from the stomach, acting on the GHS-R1a). Research peptides target both arms: GH-axis reference and CJC-1295 (GHRH analogs); ipamorelin, GHRP-6, and hexarelin (ghrelin-receptor agonists).
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with PEPPUDEX evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Goldspink and Hill multi-paper evidence base for MGF-induced satellite cell activation and local hypertrophy after mechanical loading.
Intramuscular MGF injections produce local hypertrophy in rodent and rabbit models.
No completed long-term human Phase 3 trials.
MECHANISM Q+A
▶ What is PEG-MGF?
PEG-MGF is a PEGylated form of mechano growth factor (MGF), the IGF-1Ec splice variant produced locally in muscle in response to mechanical loading or injury. PEGylation extends the otherwise sub-30-minute half-life to support practical research dosing.
▶ PEG-MGF vs IGF-1 LR3 · which is better?
Different mechanisms. IGF-1 LR3 is a systemic IGF-1R agonist that drives whole-body anabolism. PEG-MGF acts more locally on satellite-cell activation at the site of injection or injury and does not produce the same systemic IGF-1R signaling. Research protocols select between them based on the local-vs-systemic research design.
▶ What is the half-life of PEG-MGF?
Several days, depending on the PEG conjugate. Native MGF has a half-life under 30 minutes; the PEGylation strategy extends systemic exposure to support practical dosing in animal-model research.
▶ Why is PEG-MGF injected locally?
MGF is the local IGF-1 variant produced in response to muscle loading. Local intramuscular injection at the target muscle group is the standard research approach to maximize satellite-cell activation at that specific site rather than driving systemic IGF-1R signaling.
CITED LITERATURE
- Goldspink G, Yang SY. Mechano growth factor and a method for improvement of muscle. J Musculoskelet Neuronal Interact 2002. link
- Hill M, Wernig A, Goldspink G. Muscle satellite (stem) cell activation during local tissue injury and repair. J Anat 2003. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25